An Update From Our Team Regarding COVID-19 – California Governor Gavin Newsom issued a mandatory statewide order to ‘stay at home’ effective Thursday, March 19th. Governor Newsome has declared a full shutdown of non-essential … Read More
![](https://artemis-research.com/wp-content/uploads/2020/07/iStock-911834392df-scaled-e1594855007369.jpg)
An Update From Our Team Regarding COVID-19 – California Governor Gavin Newsom issued a mandatory statewide order to ‘stay at home’ effective Thursday, March 19th. Governor Newsome has declared a full shutdown of non-essential … Read More
Categories: News and Events
U.S. FDA approves Eisai’s DayVigo (Lemborexant) for the treatment of insomnia in adult patients! The FDA approved the new drug application for its in-house discovered and developed orexin receptor antagonist DayVigo (lemborexant). DayVigo was … Read More
Categories: News and Events
Idorsia announces positive results in the first Phase 3 study of daridorexant with improved overall sleep and daytime performance of patients with insomnia! We are very pleased to share with you the top line … Read More
Categories: News and Events
Corporate Office
770 Washington St, Ste 200
San Diego, CA 92103
Tel: 858-278-3647
Fax: 619-629-0512
San Diego Location
770 Washington Street, Suite 300
San Diego, CA 92103
Tel: 858-278-3647
Fax: 858-278-3660
Patient Recruitment: 1-855- DoStudies (1-855-367-8834)
Riverside Location
11748 Magnolia Ave, Suite D
Riverside, CA 92503
Tel: 951-374-1190
Fax: 951-374-7245
Patient Recruitment: 1-855- DoStudies (1-855-367-8834)
Artemis Institute is a Headlands Research Site
El Insituto de Artemis es una sucursal de Headlands Research
© 2024 Artemis Institute for Clinical Research • Accessibility Feedback • Developed by TinyFrog